A platform company developing first-in-class biologics against severe neovascular and fibrotic disorders
About us
Founding team
A complementary team of 2 scientists and 2 business professionals
Zaki Sellam
CEO and President
of the Executive Board
Strategic positioning of the company, partnerships and negotiations
Anna Kamenskaya
Chief Operating Officer
Ensuring that R&D and operations of the company are carried out according to the strategic plan defined by the Board of Directors
Olivier Léger
Chief Scientific Officer
Leveraging wide experience and a strong track record in antibody engineering to develop KBs platform
Gilles Pagès
Senior Scientist
Bringing 20+ years of translational research in cancer biology to advance Kekkan’s products towards the clinic
The Translational Advisory Board
The TAB is a consultative scientific committee composed of scientists and clinicians who assist the founders with all scientific issues by providing advice and recommendations.
Daniel Olive, MD, PHD
Head of the Immunity and Cancer lab, CRCM
Professor of Immunology and Director of the Oncology Research Programs at Aix Marseille University.
Scientific Founder of ImCheck.
Delphine Borchiellini
Medical Oncology
Head of Department of Clinical Research and Innovation at Centre Antoine-Lacassagne, Nice
Bernard Escudier
Medical Oncology at Gustav Roussy Cancer Research Centre
Board member at Kidney Cancer Association (KCA)
President of the A.R.Tu.R association association A.R.Tu.R (association of researchers focused on kidney tumours).
Camillo Porta
Full Professor of Medical Oncology at the A. Moro University of Bari in Italy
Head of the Division of Medical Oncology at the AOU Consorziale Policlinico di Bari,President of the Italian Nephro-Oncology Group (GION)